H3C WA530, Compliance And Safety Manual

Page: 3 / 51

i
Contents
Safety Information/Sicherheits informationen/
安全信
息
/
安全情報
/
안전 정보
/Informations relatives à la
sécurité/ Informazioni di sicurezza/ Información de
seguridad/Informações de segurança/
Қауіпсіздік
туралы ақпарат / Информация о безопасности /
Інформація з технічної безпеки / Güvenlik Bilgileri 1
Overview/Überblick/ 概述 / 概要 / 개요 /
Présentation/Panoramica/Descripción general/Visão
geral/
Шолу / Обзор / Огляд / Genel Bak ı ş ········································· 1
Warning Symbol Conventions/ Erläuterung der Symbole/
应用惯例
/
本書で使用されている規約 / 사용되는규칙 / Conventions
utilisées/Convenzioni utilizzate/
Convenciones empleadas/Convenções utilizadas/
Келісімдер
бойынша қолданылатын белгі / Используемые
символы / Используемые символы / Geleneksel Uyar ı Sembolleri 5
Important Safety Information/Wichtige Sicherheitshinweise/ 重要安
全信息
/
重要な安全情報
/
중요한 안전 정보
/Informations importantes
relatives à la sécurité/Informazioni di sicurezza
importanti/ Información importante de seguridad/Informações de
segurança importantes/
Қауіпсіздік туралы
маңызды ақпарат / Важные сведения о безопасности / Важлива
інформація з технічної безпеки / Önemli Güvenlik Bilgileri ······· 10
Electricity Safety/Elektrische Sicherheit/ 用电安全 / 電気面の安全 / 전기
안전
/Sécurité électrique/Sicurezza elettrica/Seguridad
eléctrica/Segurança elétrica/ Электр қауіпсіздігі /
Электробезопасность / Техніка електробезпеки / Elektrik Güvenli ğ i · 20
Hazardous Voltage/Gefährliche Spannungen / 危险电压 / 危険電圧
/
위험 전압
/ Tension dangereuse/ Tensione pericolosa/ Tensión
peligrosa/ Tensión peligrosa / Қауіпті кернеу / Опасное
напряжение / Небезпечна напруга / Tehlikeli Voltaj ················· 20
Regulatory Compliance Information ·················· 22
Regulatory compliance standards ·············································· 22
European Directives compliance ················································ 22
EU Country Restriction in 2.4GHz band ································ 26
EU Country Restriction in 5GHz band ·································· 26
FDA ·············································································· 27